Illustrated Neuropathologic Diagnosis of Alzheimer's Disease

As of 2022, the prevalence of Alzheimer's disease (AD) among individuals aged 65 and older is estimated to be 6.2 million in the United States. This figure is predicted to grow to 13.8 million by 2060. An accurate assessment of neuropathologic changes represents a critical step in understanding...

Full description

Saved in:
Bibliographic Details
Published inNeurology international Vol. 15; no. 3; pp. 857 - 867
Main Authors Doher, Nicholas, Davoudi, Vahid, Magaki, Shino, Townley, Ryan A, Haeri, Mohammad, Vinters, Harry V
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 12.07.2023
MDPI
Subjects
AD neuropathologic diagnosis
Alzheimer's disease
Autopsies
Biomarkers
Cognitive ability
Dementia
Metabolism
Neurodegeneration
Neuropathology
Opinion
Pathology
Proteins
tauopathy
neurodegeneration
dementia
tauopathy
Alzheimer’s disease
AD neuropathologic diagnosis
Online AccessGet full text

Cover

More Information
Summary:As of 2022, the prevalence of Alzheimer's disease (AD) among individuals aged 65 and older is estimated to be 6.2 million in the United States. This figure is predicted to grow to 13.8 million by 2060. An accurate assessment of neuropathologic changes represents a critical step in understanding the underlying mechanisms in AD. The current method for assessing postmortem Alzheimer's disease neuropathologic change follows version 11 of the National Alzheimer's Coordinating Center (NACC) coding guidebook. Ambiguity regarding steps in the ABC scoring method can lead to increased time or inaccuracy in staging AD. We present a concise overview of how this postmortem diagnosis is made and relate it to the evolving understanding of antemortem AD biomarkers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2035-8385
2035-8377
2035-8377
DOI:10.3390/neurolint15030054